Series A for Munich-based medical technology start-up Mecuris

Munich — Mecu­ris GmbH, a Munich-based medi­cal tech­no­logy start-up focu­sing on the digi­tiza­tion of pros­the­ses and ortho­tics, successfully closes a Series A finan­cing round of €3.6 million. In addi­tion to the exis­ting seed inves­tors Bayern Kapi­taland High-Tech Grün­der­fonds (HTGF), Vesa­lius Bioca­pi­tal, Mulcan Inter­na­tio­nal Invest­ments and one of the top five hospi­tal chains in Germany are newly on board.

Every pati­ent is unique. The requi­re­ments that ortho­pe­dic tech­ni­ci­ans have to meet in their care are ther­e­fore just as complex — with constantly incre­asing cost and time pres­sure. For this reason, off-the-shelf ortho­ses or pros­the­ses have often been used up to now. They serve their purpose, but do not fit ideally.

This is where Mecu­ris inter­venes in the supply process. The young company aims to signi­fi­cantly improve the quality of life for pati­ents while saving ortho­pe­dic tech­ni­ci­ans time and money. The aim is to work toge­ther with ortho­pe­dic tech­ni­ci­ans and wearers to design pati­ent-speci­­fic ortho­ses and pros­the­ses that are as indi­vi­dual in their func­tion­a­lity as they are in their design, color and struc­ture. To this end, Mecu­ris provi­des ortho­tists with an easy-to-use online plat­form, the Mecu­ris Solu­tion Plat­form, with which they can tailor ortho­ses and pros­the­ses. These are manu­fac­tu­red using 3D prin­ting and deli­vered within a few days. In addi­tion, the start-up offers services for medi­cal supply stores to trans­fer ortho­pe­dic products into a digi­tal process chain, bring them to market quickly and make them scalable in sales.

The approach of using and mone­tiz­ing digi­tiza­tion for perso­na­li­zed ortho­tics and prosthe­tics has convin­ced the new and exis­ting inves­tors. The foun­ding team was able to attract three new inves­tors for the Series A finan­cing: Vesa­lius Bioca­pi­tal III SICAR, MII Mulcan Inter­na­tio­nal Invest­ments GmbH and one of the five largest hospi­tal chains in Germany and Europe. The latter aims to open up digi­tiza­tion for its part­ners — the medi­cal supply stores. In addi­tion, the seed inves­tors Bayern Kapi­tal GmbH and High-Tech Grün­der­fonds Manage­ment GmbH (HTGF) have contin­ued to support the company’s goals.

Mecu­ris will use the proceeds from the finan­cing round to deve­lop the Euro­pean market and streng­then sales. In addi­tion, the start-up will conti­nue to deve­lop new digi­tal solu­ti­ons to comple­ment its own port­fo­lio and fill market gaps that other play­ers have not yet been able to serve.

About Mecu­ris GmbH
Mecu­ris works closely with certi­fied ortho­tists (OTs) to bring ortho­tics & prosthe­tics into the digi­tal age. By bund­ling 3D tech­no­lo­gies in an intui­tive Mecu­ris Solu­tion Plat­form, Mecu­ris OTs are able to design custo­mi­zed ortho­ses & pros­the­ses in a cost- and time-saving way, making their work much easier. OTs are enab­led on the plat­form to custo­mize product ideas for speci­fic pati­ents without CAD design skills and work with the wearer to realize design wishes. This impro­ves the quality of life of the users enorm­ously: they have the chance to quickly become active again and live their indi­vi­dua­lity. Thanks to CE marking and ISO certi­fi­ca­tion, Mecu­ris products meet the highest safety stan­dards and are reim­bur­sed by all health insu­rance compa­nies in Germany.

About Bayern Kapital
Bayern Kapi­tal GmbH, based in Lands­hut, was foun­ded in 1995 as a wholly owned subsi­diary of LfA Förder­bank Bayern on the initia­tive of the Bava­rian state govern­ment. As the venture capi­tal company of the Free State of Bava­ria, Bayern Kapi­tal provi­des equity capi­tal to the foun­ders of inno­va­tive high-tech compa­nies and young, inno­va­tive tech­no­logy compa­nies in Bava­ria. Bayern Kapi­tal curr­ently mana­ges eleven invest­ment funds with an invest­ment volume of around 325 million euros. To date, Bayern Kapi­tal has inves­ted around 290 million euros of venture capi­tal in 265 inno­va­tive tech­­no­­logy-orien­­ted compa­nies from a wide range of sectors, inclu­ding life scien­ces, soft­ware & IT, mate­ri­als & new mate­ri­als, nano­tech­no­logy and envi­ron­men­tal tech­no­logy. As a result, more than 5,000 jobs have been perma­nently crea­ted in Bava­ria in sustainable compa­nies. www.bayernkapital.de

About High-Tech Gründerfonds
High-Tech Grün­der­fonds (HTGF) is a seed inves­tor that finan­ces tech­­no­­logy-driven start-ups with high poten­tial. With a total invest­ment volume of 892.5 million euros across three funds and an inter­na­tio­nal part­ner network, HTGF has alre­ady supported 500 start-ups since 2005. Driven by their exper­tise, entre­pre­neu­rial spirit and passion, a team of expe­ri­en­ced invest­ment mana­gers and start-up experts supports the deve­lo­p­ment of young compa­nies. HTGF focu­ses on high-tech start-ups in various indus­tries, inclu­ding soft­ware, hard­ware and life sciences/chemicals.

HTGF can point to success stories such as Mister Spex, Rigon­tec, 6Wunderkinder, Next Kraft­werke and Cumu­lo­city, as well as Juniqe, an online store for art lovers. To date, exter­nal inves­tors have contri­bu­ted over EUR 1.9 billion to the HTGF port­fo­lio via around 1,400 follow-on finan­cing rounds.
www.high-tech-gruenderfonds.de

About MII Mulcan Inter­na­tio­nal Investments 
MULCAN is an inter­na­tio­nal invest­ment company focu­sed on growth invest­ments in the manu­fac­tu­ring, indus­trial and service sectors throug­hout Europe (with a parti­cu­lar empha­sis on Eastern Europe), the Middle East and other deve­lo­ping countries.
www.mulcan.de

About Vesa­lius Bioca­pi­tal Part­ners S.à r.L
Vesa­lius Bioca­pi­tal (Vesa­lius), the specia­li­zed life scien­ces venture capi­tal inves­tor, has been support­ing human health compa­nies through venture capi­tal funds since 2007. Since its incep­tion, Vesa­lius has raised over 260 million euros in three funds and contri­bu­ted to the deve­lo­p­ment of over 25 compa­nies. The invest­ment port­fo­lio is balan­ced between invest­ments in drug deve­lo­p­ment and invest­ments in non-drug deve­lo­p­ment. In addi­tion, Vesa­lius is commit­ted to provi­ding capi­tal to science-backed inno­va­tion and ambi­tious entre­pre­neurs, with a focus on an exit within five years. www.vesaliusbiocapital.com